US 10513558
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K2039/507
Quick answer
US patent 10513558 (Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Dec 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 77
- CPC classes
- A61K, A61K2039/505, A61K2039/507, A61K2039/545, A61K39/3955